[go: up one dir, main page]

SI3521282T1 - KINAZOLINSKI DERIVATI, KI SE UPORABLJAJO ZA ZDRAVLJENJE HIV-a - Google Patents

KINAZOLINSKI DERIVATI, KI SE UPORABLJAJO ZA ZDRAVLJENJE HIV-a

Info

Publication number
SI3521282T1
SI3521282T1 SI201531719T SI201531719T SI3521282T1 SI 3521282 T1 SI3521282 T1 SI 3521282T1 SI 201531719 T SI201531719 T SI 201531719T SI 201531719 T SI201531719 T SI 201531719T SI 3521282 T1 SI3521282 T1 SI 3521282T1
Authority
SI
Slovenia
Prior art keywords
derivatives used
quinazoline derivatives
treat hiv
hiv
treat
Prior art date
Application number
SI201531719T
Other languages
English (en)
Slovenian (sl)
Inventor
Petr Jansa
Petr Simon
Eric Lansdon
Yunfeng Eric Hu
Ondrej Baszczynski
Milan Dejmek
Richard L. Mackman
Original Assignee
Gilead Sciences, Inc.
Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc., Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I. filed Critical Gilead Sciences, Inc.
Publication of SI3521282T1 publication Critical patent/SI3521282T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201531719T 2014-12-24 2015-12-23 KINAZOLINSKI DERIVATI, KI SE UPORABLJAJO ZA ZDRAVLJENJE HIV-a SI3521282T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462096748P 2014-12-24 2014-12-24
EP18213309.0A EP3521282B1 (fr) 2014-12-24 2015-12-23 Dérivés de quinazoline utilisés pour traiter le vih

Publications (1)

Publication Number Publication Date
SI3521282T1 true SI3521282T1 (sl) 2021-11-30

Family

ID=55305044

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201530560T SI3237398T1 (sl) 2014-12-24 2015-12-23 Derivati kinazolina uporabljeni za zdravljenje HIV
SI201531719T SI3521282T1 (sl) 2014-12-24 2015-12-23 KINAZOLINSKI DERIVATI, KI SE UPORABLJAJO ZA ZDRAVLJENJE HIV-a

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201530560T SI3237398T1 (sl) 2014-12-24 2015-12-23 Derivati kinazolina uporabljeni za zdravljenje HIV

Country Status (41)

Country Link
US (5) US9730936B2 (fr)
EP (4) EP3521282B1 (fr)
JP (2) JP6367489B2 (fr)
KR (2) KR102049476B1 (fr)
CN (2) CN111574464A (fr)
AR (1) AR103252A1 (fr)
AU (1) AU2015371198B2 (fr)
BR (1) BR102015032361B1 (fr)
CA (1) CA2972021C (fr)
CL (1) CL2017001675A1 (fr)
CO (1) CO2017006214A2 (fr)
CR (1) CR20170281A (fr)
CU (1) CU20170089A7 (fr)
CY (1) CY1124726T1 (fr)
DK (1) DK3521282T3 (fr)
DO (1) DOP2017000151A (fr)
EA (2) EA035746B1 (fr)
EC (1) ECSP17039611A (fr)
ES (3) ES2900810T3 (fr)
HK (1) HK1244001B (fr)
HR (1) HRP20211543T1 (fr)
HU (1) HUE058296T2 (fr)
IL (2) IL253059B (fr)
LT (1) LT3521282T (fr)
MA (1) MA48448A (fr)
MD (1) MD4650B1 (fr)
MX (2) MX367574B (fr)
MY (1) MY189761A (fr)
NZ (1) NZ733174A (fr)
PE (1) PE20171306A1 (fr)
PH (1) PH12017501191B1 (fr)
PL (3) PL3521282T3 (fr)
PT (2) PT3521282T (fr)
SA (1) SA517381826B1 (fr)
SG (2) SG11201705215PA (fr)
SI (2) SI3237398T1 (fr)
SV (1) SV2017005471A (fr)
TR (1) TR201903672T4 (fr)
TW (3) TW202237569A (fr)
UA (1) UA117796C2 (fr)
WO (1) WO2016105564A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
EA032430B1 (ru) 2014-12-24 2019-05-31 Джилид Сайэнс, Инк. Конденсированные пиримидины для лечения вич
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
EP3597646B1 (fr) 2016-08-19 2023-06-21 Gilead Sciences, Inc. Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus vih
AR112413A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
WO2019161017A1 (fr) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Dérivés de pyridine et leur utilisation pour le traitement d'une infection par le vih
US10696657B2 (en) 2018-02-16 2020-06-30 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
US20210353626A1 (en) * 2018-04-20 2021-11-18 The Regents Of The University Of California Beta-adrenergic receptor allosteric modulators
TWI842721B (zh) 2018-07-16 2024-05-21 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
US20230065740A1 (en) 2018-12-28 2023-03-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
WO2020197991A1 (fr) 2019-03-22 2020-10-01 Gilead Sciences, Inc. Composés de carbamoylpyridone tricyclique pontés et leur utilisation pharmaceutique
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
US20200347036A1 (en) 2019-04-17 2020-11-05 Gilead Sciences, Inc. Solid forms of an hiv protease inhibitor
US11807625B2 (en) 2019-11-26 2023-11-07 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
TW202421168A (zh) 2020-03-20 2024-06-01 美商基利科學股份有限公司 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法
MX2022013321A (es) 2020-04-24 2022-11-30 Sumitomo Pharma Co Ltd Derivado de 2-heteroarilaminoquinazolinona.
TW202502766A (zh) 2020-06-25 2025-01-16 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
WO2022103758A1 (fr) 2020-11-11 2022-05-19 Gilead Sciences, Inc. Procédés d'identification des patients vih sensibles à la thérapie avec des anticorps visant le site de liaison cd4 de la gp120
CN118369316A (zh) 2021-12-03 2024-07-19 吉利德科学公司 Hiv病毒感染的治疗性化合物
CA3235937A1 (fr) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Composes therapeutiques contre l'infection par le virus du vih
JP7765637B2 (ja) 2021-12-03 2025-11-06 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖウイルス感染症のための治療化合物
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TW202434566A (zh) 2022-07-01 2024-09-01 美商基利科學股份有限公司 可用於hiv病毒感染之疾病預防性或治療性治療的治療性化合物
AU2023330037A1 (en) 2022-08-26 2025-03-06 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
EP4598934A1 (fr) 2022-10-04 2025-08-13 Gilead Sciences, Inc. Analogues de 4'-thionucléosides et leur utilisation pharmaceutique
AR132464A1 (es) 2023-04-19 2025-07-02 Gilead Sciences Inc Régimen de dosificación de inhibidor de la cápside
WO2024249592A1 (fr) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Dérivés de quinazolinyl-indazole en tant que composés thérapeutiques pour le vih
TW202504592A (zh) 2023-05-31 2025-02-01 美商基利科學股份有限公司 固體形式
WO2025029247A1 (fr) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Régime hebdomadaire de lénacapavir pour le traitement et la prévention du vih
WO2025042394A1 (fr) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Schéma posologique d'un inhibiteur de capside du vih
US20250122219A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080850A1 (fr) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Composés de carbamoylpyridone tricycliques pontés et leurs utilisations
TW202515549A (zh) 2023-10-11 2025-04-16 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2025137245A1 (fr) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Formes solides d'inhibiteurs de l'intégrase du vih
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250333424A1 (en) 2024-03-01 2025-10-30 Gilead Sciences, Inc. Antiviral compounds
WO2025184447A1 (fr) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Compositions pharmaceutiques comprenant des inhibiteurs de l'intégrase du vih
WO2025260028A1 (fr) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Compositions pharmaceutiques comprenant des inhibiteurs de l'intégrase du vih

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ197420A (en) 1980-07-01 1984-04-27 Ici Australia Ltd -(quinazolin-(2-or 4-)(oxy,ylthio or amino)phen(oxy or ylthio)alkanoic acid derivatives
JPH11209350A (ja) 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
AU7031500A (en) 1999-09-23 2001-04-24 Astrazeneca Ab Therapeutic quinazoline compounds
JP2003514901A (ja) 1999-11-22 2003-04-22 ワーナー−ランバート・カンパニー キナゾリン類およびシクリン依存性キナーゼ酵素を阻害するためのその使用
GB0002032D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
JP2004505110A (ja) 2000-08-02 2004-02-19 セルテック　アール　アンド　ディ　リミテッド ３位置換イソキノリン−１−イル誘導体
EP1318984A1 (fr) 2000-09-20 2003-06-18 MERCK PATENT GmbH 4-amino-quinazolines
AU2003255482A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
DK1628685T3 (da) 2003-04-25 2011-03-21 Gilead Sciences Inc Antivirale phosphonatanaloge
WO2004108711A1 (fr) 2003-06-05 2004-12-16 Astrazeneca Ab Derives pyrazinile quinazoline destines au traitement de tumeurs
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
AU2005298637B8 (en) 2004-10-29 2012-12-06 Janssen Sciences Ireland Uc HIV inhibiting bicyclic pyrimidine derivatives
WO2006071095A1 (fr) 2004-12-31 2006-07-06 Sk Chemicals Co., Ltd. Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité
US7816352B2 (en) 2005-03-10 2010-10-19 The Regents Of The University Of California Apoptosis inhibitors
JP5079500B2 (ja) 2005-04-28 2012-11-21 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
MX2008000017A (es) 2005-06-28 2008-03-26 Sanofi Aventis Derivados de isoquinolina como inhibidores de rho-cinasa.
NI200800025A (es) 2005-07-26 2009-03-03 Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
EP2044028B1 (fr) 2006-01-27 2012-05-16 Fibrogen, Inc. Cyanoisoquinolines en tant que stabilisateurs du facteur induit par l' hypoxie
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
JP2009535393A (ja) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換２−アミノ縮合複素環式化合物
EP2079724B1 (fr) 2006-07-20 2010-05-26 Amgen Inc. Composés de pyridone substitués et procédés d'utilisation
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
WO2008050808A1 (fr) 2006-10-24 2008-05-02 Kyowa Hakko Kirin Co., Ltd. Dérivé de 2-aminoquinazoline
CN101573338B (zh) 2006-12-27 2013-03-20 塞诺菲-安万特股份有限公司 环烷基胺取代的异喹诺酮和异喹啉酮衍生物
BRPI0722064A2 (pt) 2006-12-27 2014-04-01 Sanofi Aventis Derivados de isoquinolona substituídos por cicloalquilamina
AU2007338406B2 (en) 2006-12-27 2012-08-09 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of Rho-kinase
WO2008086462A2 (fr) 2007-01-11 2008-07-17 Wyeth Dérivés de quinalozine substitués par amino en tant qu'inhibiteurs de la voie b-caténine/tcf-4 et agents de traitement du cancer
JP2010523529A (ja) 2007-04-06 2010-07-15 ノバルティス アーゲー プロテインキナーゼ調節剤としての２，６−ナフチリジン誘導体
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
WO2009062285A1 (fr) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibiteurs de la réplication du virus de l'immunodéficience humaine
WO2009131173A1 (fr) 2008-04-23 2009-10-29 協和発酵キリン株式会社 Dérivé de 2-aminoquinazoline
MX315904B (es) 2008-05-30 2013-11-29 Amgen Inc Inhibidores de fosfoinosituro-3 cinasa.
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
JP5335082B2 (ja) 2008-08-15 2013-11-06 ビーエーエスエフ ソシエタス・ヨーロピア ナノスケールの有機固体粒子の製造方法
CA2745295C (fr) 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulateurs de recepteurs de type toll (tlr)
EP2381943A1 (fr) 2008-12-29 2011-11-02 Fovea Pharmaceuticals Composés quinazoline substitués
EP2416660B1 (fr) 2009-04-07 2014-07-02 Infinity Pharmaceuticals, Inc. Inhibiteurs d'amide d'hydrolase d'acide gras
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
WO2011035416A1 (fr) 2009-09-25 2011-03-31 Aegera Therapeutics Inc. Composés modulateurs de la hsp90, compositions, procédés et utilisations correspondants
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
AR081960A1 (es) 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
US9102617B2 (en) 2010-06-25 2015-08-11 Rutgers, The State University Of New Jersey Antimicrobial agents
EP2588450B1 (fr) 2010-07-02 2017-05-24 Gilead Sciences, Inc. Derivatives de l'acide napht-2yl-acétique pour traitement du sida
SG186821A1 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
WO2012044090A2 (fr) 2010-09-29 2012-04-05 크리스탈지노믹스(주) Nouveau composé d'aminoquinazoline possédant une action inhibitrice de la protéine kinase
KR20120038060A (ko) 2010-10-13 2012-04-23 롬엔드하스전자재료코리아유한회사 신규한 유기 전자재료용 화합물 및 이를 포함하는 유기 전계 발광 소자
JP6026427B2 (ja) 2010-12-17 2016-11-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 置換６，６−縮合窒素複素環化合物及びその使用
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
SG194512A1 (en) 2011-04-21 2013-12-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9399645B2 (en) 2011-12-20 2016-07-26 Boehringer Ingelheim International Gmbh Inhibitors of HIV replication
CA2850881C (fr) 2012-04-20 2021-02-16 Gilead Sciences, Inc. Derives d'acide benzothiazol-6-yl acetique et leur utilisation dans le traitement d'une infection par le vih
SI3067358T1 (sl) 2012-12-21 2019-12-31 Gilead Sciences, Inc. Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba
AR094311A1 (es) 2012-12-27 2015-07-22 Japan Tobacco Inc Derivados de tetrahidroespiro-ciclopropil-pirido[1,2-a]pirazina inhibidores de la integrasa del hiv
EP2769723A1 (fr) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Composés utilisés pour inhiber un assemblage de capside du VIH
EP2769722A1 (fr) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Composés utilisés pour inhiber un assemblage de capside du VIH
US9914709B2 (en) 2013-06-21 2018-03-13 Yale University Compositions and methods of treating HIV-1 infections using same
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
EA032430B1 (ru) 2014-12-24 2019-05-31 Джилид Сайэнс, Инк. Конденсированные пиримидины для лечения вич
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物

Also Published As

Publication number Publication date
SA517381826B1 (ar) 2021-10-21
CA2972021A1 (fr) 2016-06-30
WO2016105564A1 (fr) 2016-06-30
TW201636328A (zh) 2016-10-16
AU2015371198B2 (en) 2018-09-27
MY189761A (en) 2022-03-03
JP6367489B2 (ja) 2018-08-01
TR201903672T4 (tr) 2019-04-22
MX2017008521A (es) 2018-03-01
BR102015032361B1 (pt) 2021-12-21
US10548898B2 (en) 2020-02-04
US20160250215A1 (en) 2016-09-01
DK3521282T3 (da) 2021-09-27
SI3237398T1 (sl) 2019-04-30
KR20170131351A (ko) 2017-11-29
CO2017006214A2 (es) 2017-10-20
US20200360383A1 (en) 2020-11-19
CY1124726T1 (el) 2022-07-22
JP2018168181A (ja) 2018-11-01
MA48448A (fr) 2021-04-28
CU20170089A7 (es) 2017-11-07
KR20190133068A (ko) 2019-11-29
HK1244001B (en) 2020-01-10
ES2964395T3 (es) 2024-04-05
LT3521282T (lt) 2021-11-25
KR102049476B1 (ko) 2019-11-28
PL3237398T3 (pl) 2019-05-31
CA2972021C (fr) 2020-04-28
TWI699355B (zh) 2020-07-21
EA201791256A1 (ru) 2018-04-30
DOP2017000151A (es) 2017-09-15
EA035746B1 (ru) 2020-08-05
CR20170281A (es) 2017-11-08
NZ733174A (en) 2018-12-21
UA117796C2 (uk) 2018-09-25
US11304948B2 (en) 2022-04-19
EP3237398B1 (fr) 2018-12-19
MX2019009932A (es) 2019-10-02
PL3521282T3 (pl) 2022-01-03
US20230043136A1 (en) 2023-02-09
IL269635B (en) 2021-04-29
IL253059A0 (en) 2017-08-31
HUE058296T2 (hu) 2022-07-28
TW202106667A (zh) 2021-02-16
IL253059B (en) 2019-10-31
AR103252A1 (es) 2017-04-26
ECSP17039611A (es) 2017-07-31
ES2715507T3 (es) 2019-06-04
EP4302830A2 (fr) 2024-01-10
US20170354656A1 (en) 2017-12-14
CL2017001675A1 (es) 2018-05-11
PE20171306A1 (es) 2017-09-05
EP3960735A1 (fr) 2022-03-02
EP3960735B1 (fr) 2023-09-13
BR102015032361A8 (pt) 2021-08-31
TWI770552B (zh) 2022-07-11
HRP20211543T1 (hr) 2022-01-07
EP3521282B1 (fr) 2021-08-25
CN111574464A (zh) 2020-08-25
SG10202101143VA (en) 2021-03-30
MD20170070A2 (ro) 2017-12-31
CN107278201A (zh) 2017-10-20
PT3521282T (pt) 2021-11-29
BR102015032361A2 (pt) 2016-07-05
MX367574B (es) 2019-08-27
PH12017501191A1 (en) 2018-03-05
TW202237569A (zh) 2022-10-01
CN107278201B (zh) 2020-05-19
EP4302830A3 (fr) 2024-03-13
EA202091115A1 (ru) 2021-01-29
SV2017005471A (es) 2018-01-18
WO2016105564A8 (fr) 2016-10-06
PL3960735T3 (pl) 2024-03-18
EP3960735C0 (fr) 2023-09-13
PT3237398T (pt) 2019-03-06
SG11201705215PA (en) 2017-07-28
US10206926B2 (en) 2019-02-19
KR102288855B1 (ko) 2021-08-11
ES2900810T3 (es) 2022-03-18
US20190134035A1 (en) 2019-05-09
PH12017501191B1 (en) 2021-08-06
IL269635A (en) 2019-11-28
JP2018500358A (ja) 2018-01-11
US9730936B2 (en) 2017-08-15
EP3237398A1 (fr) 2017-11-01
MD4650B1 (ro) 2019-09-30
AU2015371198A1 (en) 2017-07-13
EP3521282A1 (fr) 2019-08-07

Similar Documents

Publication Publication Date Title
IL269635B (en) History of conazole used to treat hiv
IL253052A0 (en) Isoquinoline compounds for the treatment of hiv
SG11201606199SA (en) Ketoprofen-containing poultice
IL258137A (en) HIV treatment measures
GB201411027D0 (en) Treatment
PL3131633T3 (pl) Pochodne MMF etylenoglikoli
GB2522473B (en) Improvements to windposts
GB2522039B (en) I-beam
GB201412411D0 (en) Treatment
GB201401124D0 (en) Anti-inflammatory solution
AU5296P (en) LowstenoGL Grevillea stenomera
AU5297P (en) FlatstenoGL Grevillea stenomera
GB2520781B (en) Improvements to hydro-turbines
AU2014903428A0 (en) Treatment of HIV
GB201414186D0 (en) Secure tip
GB201405489D0 (en) Able to go
GB201421232D0 (en) Retro-reflector
GB201409013D0 (en) My site
GB201406790D0 (en) Laser treatment
GB201409028D0 (en) Easy see mouse
GB201413317D0 (en) Atheroscierosis treatment
GB201412410D0 (en) Treatment
GB201400240D0 (en) Treatment
GB201400241D0 (en) Treatment
GB201400239D0 (en) Treatment